Profusa, Inc. (PFSA) has announced a Letter of Intent to acquire PanOmics, a multi-omics diagnostics platform, from BioInsights LLC for $30 million, marking a significant strategic move into molecular diagnostics. Following this announcement, PFSA shares surged by nearly 123%, closing at $1.69. The acquisition will be executed through equity securities, and BioInsights will also receive a 3% royalty on net revenue, along with the right to nominate a Board member.
This acquisition is pivotal for Profusa as it aims to enhance its real-time biochemistry monitoring capabilities, particularly in the field of pancreatic cancer. The move positions Profusa at the intersection of biosensing, diagnostics, and precision medicine, potentially broadening its market reach and application in treating multiple indications.
For market professionals, this development underscores the growing trend of consolidation in the health tech sector, highlighting opportunities for companies that can integrate diagnostics with existing monitoring technologies.
Source: nasdaq.com